triple‐negative breast cancer (TNBC) is defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER2) negative breast cancer, which accounts for about 10%‐17% of breast cancer molecular subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.